One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Morphic Holding logo
Morphic Holding MORF
report update icon

Quarterly report 2024-Q2
added 05-30-2026

Morphic Holding Financial Ratios 2023-2011 | MORF

Annual Financial Ratios Morphic Holding

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-10.0 -27.9 -14.9 -24.6 -5.9 - - - - - - - -

P/S

2909.6 23.3 72.1 24.6 15.0 - - - - - - - -

EPS

-3.6 -1.6 -2.7 -1.5 -2.7 -4.3 - - - - - - -

EV (Enterprise Value)

1.48 B 1.61 B 1.35 B 1.1 B 259 M -83.9 M 52.9 M - - - - - -

EBITDA per Share

-4.19 -1.64 -2.65 -1.51 -2.87 -5.08 - - - - - - -

EV/EBITDA

-8.3 -25.8 -14.2 -23.9 -5.6 15.4 - - - - - - -

PEG

-0.49 - - -0.5 0.15 - - - - - - - -

P/B

2.2 4.7 4.2 7.6 1.8 - - - - - - - -

P/CF

-13.5 -16.3 -17.1 -24.1 -6.1 - - - - - - - -

ROE %

-21.82 -16.91 -28.38 -30.99 -30.75 10.17 - - - - - - -

ROA %

-21.05 -16.02 -22.41 -18.57 -17.51 -2.82 - - - - - - -

ROCE %

-25.64 -18.16 -28.45 -32.49 -22.16 -3.87 - - - - - - -

Current Ratio

28.3 18.9 4.8 2.5 2.3 1.9 - - - - - - -

DSO

159.4 7.1 88.7 43.8 37.3 - - - - - - - -

Operating Cycle

159.4 7.1 88.7 43.8 37.3 - - - - - - - -

Cash Conversion Cycle

159.4 7.1 88.7 43.8 37.3 - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Morphic Holding

2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-1.15 -0.91 - -0.73 -0.92 -0.9 - -0.78 0.7 -0.85 - -0.69 -0.77 -0.63 -0.57 0.18 -0.52 -0.55 -0.66 -0.3 -4.73 -2.77 -4.27 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-1.29 -1.07 - -0.89 -1.06 -0.97 - -0.8 0.7 -0.85 - -0.67 -0.76 -0.63 -0.56 0.19 -0.52 -0.58 -0.68 -0.31 -5.05 -3.17 -3.26 - -3.28 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-26.49 -25.65 -18.83 -27.05 -15.13 -19.82 -11.35 -18.50 -18.28 -30.96 -20.92 -33.14 -21.88 -27.68 -34.98 -36.83 -46.50 -18.41 -9.03 15.21 34.24 31.80 50.40 13.47 11.86 14.91 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-25.63 -24.89 -18.26 -25.97 -14.62 -17.33 -9.16 -14.87 -13.48 -24.60 -16.67 -23.99 -15.87 -17.02 -19.69 -20.39 -26.21 -24.01 -18.81 -13.61 -13.94 -11.95 -2.82 -3.74 -3.29 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-31.03 -29.67 -21.59 -30.22 -17.24 -21.13 -11.94 -19.12 -18.49 -31.06 -20.95 -33.33 -22.32 -28.60 -36.71 -38.93 -48.96 -18.88 -9.35 16.61 36.45 32.58 51.95 13.65 11.92 15.02 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

23.4 35.6 28.3 36.4 38.7 28.6 18.9 16.1 16.0 4.7 4.8 5.0 4.8 5.1 2.5 2.4 2.2 2.3 2.3 2.6 1.7 2.3 1.9 1.9 1.9 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

- - - - - 84.2 - 37.7 2.3 83.2 - 57.4 48.3 140.8 69.2 9.2 42.8 58.3 - 26.6 36.2 26.1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

- - - - - 84.2 - 14.7 1.5 83.2 - 57.4 48.3 140.8 113.1 25.9 86.8 87.9 - 55.8 56.8 26.1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

- - - - - 84.2 - 14.7 1.5 83.2 - 57.4 48.3 140.8 113.1 25.9 86.8 87.9 - 55.8 56.8 26.1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Morphic Holding, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Evelo Biosciences Evelo Biosciences
EVLO
- -14.46 % $ 27.9 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Novan Novan
NOVN
- -24.84 % $ 2.64 M usaUSA
Genocea Biosciences Genocea Biosciences
GNCA
- -15.0 % $ 3.04 M usaUSA
Eiger BioPharmaceuticals Eiger BioPharmaceuticals
EIGR
- -9.21 % $ 2.55 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
BELLUS Health BELLUS Health
BLU
- - $ 2.47 B canadaCanada
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Intra-Cellular Therapies Intra-Cellular Therapies
ITCI
- - $ 13.6 B usaUSA
IGM Biosciences IGM Biosciences
IGMS
- - $ 76.9 M usaUSA
Marinus Pharmaceuticals Marinus Pharmaceuticals
MRNS
- - $ 29.6 M usaUSA
Merrimack Pharmaceuticals Merrimack Pharmaceuticals
MACK
- - $ 216 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
- - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
- - $ 728 M usaUSA
Rubius Therapeutics Rubius Therapeutics
RUBY
- -33.55 % $ 7.81 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
TRACON Pharmaceuticals TRACON Pharmaceuticals
TCON
- -1.38 % $ 46.8 M usaUSA
Mirati Therapeutics Mirati Therapeutics
MRTX
- - $ 3.3 B usaUSA
Revance Therapeutics Revance Therapeutics
RVNC
- - $ 309 M usaUSA
Allogene Therapeutics Allogene Therapeutics
ALLO
$ 1.09 -8.82 % $ 240 M usaUSA
InVivo Therapeutics Holdings Corp. InVivo Therapeutics Holdings Corp.
NVIV
- -37.48 % $ 476 K usaUSA
Epizyme Epizyme
EPZM
- - $ 249 M usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Processa Pharmaceuticals Processa Pharmaceuticals
PCSA
$ 1.86 -4.07 % $ 2.44 M usaUSA
Forward Pharma A/S Forward Pharma A/S
FWP
- -0.75 % $ 18.7 M danmarkDanmark
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
- 1.02 % $ 90.8 M britainBritain
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
- - $ 154 M usaUSA
Oyster Point Pharma Oyster Point Pharma
OYST
- - $ 300 M usaUSA
Nabriva Therapeutics plc Nabriva Therapeutics plc
NBRV
- - $ 4.55 M irlandaIrlanda
Intercept Pharmaceuticals Intercept Pharmaceuticals
ICPT
- - $ 643 M usaUSA
NGM Biopharmaceuticals NGM Biopharmaceuticals
NGM
- - $ 127 M usaUSA
Regulus Therapeutics Regulus Therapeutics
RGLS
- - $ 155 M usaUSA
9 Meters Biopharma 9 Meters Biopharma
NMTR
- -42.97 % $ 1.05 M usaUSA
Chinook Therapeutics Chinook Therapeutics
KDNY
- - $ 2.6 B usaUSA
Lumos Pharma Lumos Pharma
LUMO
- - $ 35.3 M usaUSA
Syros Pharmaceuticals Syros Pharmaceuticals
SYRS
- -8.44 % $ 3.4 M usaUSA
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
- -18.25 % $ 5.04 M israelIsrael
GT Biopharma GT Biopharma
GTBP
$ 4.5 -7.02 % $ 24.8 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
$ 2.96 -5.29 % $ 245 M usaUSA
Regeneron Pharmaceuticals Regeneron Pharmaceuticals
REGN
$ 904.05 -2.86 % $ 94.6 B usaUSA
Codexis Codexis
CDXS
$ 1.02 -5.56 % $ 88.9 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 28.24 -5.65 % $ 1.88 B usaUSA
CorMedix CorMedix
CRMD
$ 5.23 -7.69 % $ 377 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 48.49 -6.34 % $ 4.36 B schweizSchweiz
SIGA Technologies SIGA Technologies
SIGA
$ 2.98 -5.56 % $ 213 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA